Literature DB >> 12480080

Cholinesterase inhibitor rivastigmine enhance the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer's disease.

J Casademont1, O Miró, B Rodriguez-Santiago, P Viedma, R Blesa, F Cardellach.   

Abstract

Electron transport chain (ETC) dysfunction has been claimed to contribute to the expression of neurodegenerative disorders. We have investigated the effects of the treatment with rivastigmine, a commonly used cholinesterase inhibitor, on lymphocyte mitochondria of patients with Alzheimer's disease (AD). Increased enzymatic activities of diverse complexes and oxidative capacity of the ETC were found. Enhanced mitochondrial ETC function may contribute to the beneficial effects of rivastigmine on clinical manifestations of AD.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12480080     DOI： 10.1016/s0022-510x(02)00319-2

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN： 0022-510X            Impact factor:   3.181


  11 in total

Review 1.  Peripheral mitochondrial dysfunction in Alzheimer's disease: focus on lymphocytes.

Authors:  Kristina Leuner; Kathrin Schulz; Tanja Schütt; Johannes Pantel; David Prvulovic; Virginie Rhein; Egemen Savaskan; Christian Czech; Anne Eckert; Walter E Müller
Journal:  Mol Neurobiol       Date:  2012-07-22       Impact factor: 5.590

Review 2.  Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions.

Authors:  Jia Yao; Jamaica R Rettberg; Lauren P Klosinski; Enrique Cadenas; Roberta Diaz Brinton
Journal:  Mol Aspects Med       Date:  2011-10-21

3.  In Vitro Effects of Cognitives and Nootropics on Mitochondrial Respiration and Monoamine Oxidase Activity.

Authors:  Namrata Singh; Jana Hroudová; Zdeněk Fišar
Journal:  Mol Neurobiol       Date:  2016-09-23       Impact factor: 5.590

Review 4.  Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.

Authors:  Juan Wang; Hai-Yan Zhang; Xi-Can Tang
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

5.  Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium.

Authors:  Timothy R Mhyre; Rebekah Loy; Pierre N Tariot; Louis A Profenno; Kathleen A Maguire-Zeiss; Dabao Zhang; Paul D Coleman; Howard J Federoff
Journal:  Neurobiol Aging       Date:  2007-05-22       Impact factor: 4.673

Review 6.  Mitochondrial dysfunctions in neurodegenerative diseases: relevance to Alzheimer's disease.

Authors:  Jana Hroudová; Namrata Singh; Zdeněk Fišar
Journal:  Biomed Res Int       Date:  2014-05-12       Impact factor: 3.411

7.  Elucidating Conserved Transcriptional Networks Underlying Pesticide Exposure and Parkinson's Disease: A Focus on Chemicals of Epidemiological Relevance.

Authors:  Fangjie Cao; Christopher L Souders Ii; Veronica Perez-Rodriguez; Christopher J Martyniuk
Journal:  Front Genet       Date:  2019-01-25       Impact factor: 4.599

8.  Defective mitochondrial respiration, altered dNTP pools and reduced AP endonuclease 1 activity in peripheral blood mononuclear cells of Alzheimer's disease patients.

Authors:  Scott Maynard; Anne-Mette Hejl; Thuan-Son T Dinh; Guido Keijzers; Åse M Hansen; Claus Desler; Maria Moreno-Villanueva; Alexander Bürkle; Lene J Rasmussen; Gunhild Waldemar; Vilhelm A Bohr
Journal:  Aging (Albany NY)       Date:  2015-10       Impact factor: 5.682

9.  Mitochondrial Alterations in Peripheral Mononuclear Blood Cells from Alzheimer's Disease and Mild Cognitive Impairment Patients.

Authors:  A Delbarba; G Abate; C Prandelli; M Marziano; L Buizza; N Arce Varas; A Novelli; F Cuetos; C Martinez; C Lanni; M Memo; D Uberti
Journal:  Oxid Med Cell Longev       Date:  2016-01-06       Impact factor: 6.543

Review 10.  p53 and mitochondrial dysfunction: novel insight of neurodegenerative diseases.

Authors:  Chun-Qiu Dai; Ting-Ting Luo; Shi-Cheng Luo; Jia-Qi Wang; Sheng-Ming Wang; Yun-Hu Bai; Yan-Ling Yang; Ya-Yun Wang
Journal:  J Bioenerg Biomembr       Date:  2016-07-15       Impact factor: 2.945
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.